Alumis to Present at Leerink's 2025 Global Healthcare Conference
10. März 2025 08:00 ET
|
Alumis Inc.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
10. März 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
08. März 2025 13:00 ET
|
Regeneron Pharmaceuticals, Inc.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly...
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
08. März 2025 09:00 ET
|
Alumis Inc.
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
Tsay Keh Dene Nation partners with Tersa Earth to drive sustainable mining solutions
07. März 2025 13:44 ET
|
Tersa Earth Innovations Inc
Tsay Keh Dene Nation partners with Tersa Earth to drive sustainable mining solutions.
Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
07. März 2025 08:00 ET
|
MindRank
HANGZHOU, China and LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug...
Amaran Biotech Signs MOU with Nippon Fine Chemical
06. März 2025 22:50 ET
|
Amaran Biotech
Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generati
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
06. März 2025 16:02 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06. März 2025 16:01 ET
|
ALX Oncology
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral...
Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
06. März 2025 08:00 ET
|
Cannara Biotech (Québec) Inc.
Cannara Biotech will present at the Ventum Canadian Cannabis Conference on March 12th, 2025, showcasing its financial success, market growth, and cost adv.